ILMN : Analysis & Opinions

  1. Illumina Tops Q4 Earnings on Solid Revenues, Margin Growth - ...

    January 28, 2015
    Illumina's (ILMN) full year 2014 adjusted earnings came in at $2.74 per share, beating the Zacks Consensus Estimate by 3.4% ...
  2. Organize Price-Band Relationships In Bollinger Bands®

    January 26, 2015
    Bollinger Bands have become an enormously popular market tool since the 1990s but most traders fail to tap its true potential.
  3. Can Illumina (ILMN) Keep the Earnings Streak Alive in Q4? - Analyst ...

    January 23, 2015
    Illumina (ILMN) now expects adjusted earnings per share for full year 2014 slightly above the top end of its previously announced ...
  4. Illumina Launches MiSeq FGx for Forensic DNA Analysis - Analyst ...

    January 22, 2015
    Illumina's (ILMN) MiSeq FGx system will not only play a crucial role in solving criminal caseworks but also hold immense ...
  5. Top 3 MedTech Stocks Poised to Gain this Earnings Season - Earnings ...

    January 22, 2015
    A bipartisan group of ten senators signed on a bill to repeal the 2.3% federal excise tax on medical device makers.
  6. Will ResMed (RMD) Surprise Earnings Estimates in Q2? - Analyst ...

    January 20, 2015
    ResMed (RMD) expects to launch the AirCurve 10 platform in key global markets in the coming quarters of fiscal 2015.
  7. Illumina Unveils 3 NGS Systems, Modifies Business Strategy - ...

    January 16, 2015
    llumina's (ILMN) NextSeq 550 System is the first next generation sequencer that allows array scanning.
  8. Illumina Declares Impressive Q4, 2014 Preliminary Results - Analyst ...

    January 15, 2015
    Illumina (ILMN) estimates total revenue of $512 million for the yet to-be-reported fourth quarter, which reflects a massive ...
  9. The Biggest Biotech Companies

    January 15, 2015
    These biotech firms want to revolutionize medicine. If successful, they may see high profits, but investing in these companies ...
  10. Fluidigm's Preliminary Q4 Revenues Up Y/Y, Outlook Positive - ...

    January 14, 2015
    Fluidigm Corp (FLDM) recently announced its preliminary fourth-quarter 2014 revenues.
  11. Illumina Partners Lockheed Martin for Genomics Solutions - Analyst ...

    January 13, 2015
    Illumina Inc. (ILMN) recently formed a strategic alliance with Lockheed Martin (LMT).
  12. Affymetrix's Preliminary Q4 Revenues Outshine Estimates - Analyst ...

    January 13, 2015
    Affymetrix Inc (AFFX) recently announced preliminary revenue expectation for the fourth quarter of 2014.
  13. Fluidigm's Single-Cell Workflow to Advance Cancer Research - ...

    December 30, 2014
    The new application by Fluidigm Corp. (FLDM) will empower cancer researchers to predict cancer susceptibility, metastasis ...
  14. Affymetrix (AFFX) Touches 52-Week High on Bullish Trends - Analyst ...

    December 29, 2014
    Shares of Affymetrix Inc. (AFFX) scaled a 52-week high of $10.14 on Dec 26 and closed at $10.07, representing a healthy year-to-date ...
  15. Is Illumina (ILMN) Worth Adding to Your Portfolio? - Analyst ...

    December 16, 2014
    On Dec 10, 2014, we issued an updated research report on Illumina Inc. (ILMN).
  16. Meet The 5 Companies Loving Obamacare

    November 4, 2014
  17. Big Swings in Biotech Short Interest

    October 13, 2014
  18. MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook

    May 1, 2014
    MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook
  19. Biotechnology Stocks To Keep on the Radar

    April 23, 2014
    Health care is showing a resurgance, lead by biotechnology. Here are the opportunites to watch.
  20. Four Breakout Stocks To Watch

    February 19, 2014
    These biotechnology and pharmaceutical stocks continue to put in new highs, but indicators are diverging.
  21. Technology And Healthcare Stocks To Watch

    January 20, 2014
    Two sectors continue to dominate, and these stocks within them are still seeing exception returns.
  22. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    November 12, 2013
    Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
  23. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    September 14, 2013
    Declining short interest in Alexion Pharmaceuticals (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical ...
  24. Pricing Still A Long-Term Risk, But Illumina Continues To Build ...

    August 15, 2013
    Pricing Still A Long-Term Risk, But Illumina Continues To Build A Sequencing Fortress Between the disruptions created ...
  25. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  26. Thermo Steps Up And Seals A Deal For Life Technologies

    April 19, 2013
    Speculation has been all over the place for an M&A with LifeTech, but the final announcement is consistent with my expectations.
  27. Has Roche Said "Nein" To Illumina's Asking Price Once More?

    January 7, 2013
    Roche may have walked away from Illumina for good.
  28. Agilent's Grim Guidance Obscures Long-Term Value

    November 20, 2012
    Agilent's guidance points to another tough year.
  29. The Week In Healthcare

    August 31, 2012
    Although this has been a solid year for med-tech, some sub-sectors are starting to lag a bit during this late summer rally.
  30. Agilent Seeing Tougher Conditions, But Still A Quality Pick

    August 17, 2012
    Agilent's end markets have weakened, but the company looks well-positioned for the long term.
  31. Is There Enough Growth To Really Push Life Technologies?

    June 29, 2012
    Life Technologies isn't the growth stock people think it is, but at the right price it's a good holding.
  32. Medicine Gets Personalized

    June 28, 2012
    With our population continuing to age and grow, innovation in the healthcare sector will need to move just as fast. One such ...
  33. Neogen Is Almost Cheap

    December 30, 2011
    Neogen has to do more to validate this price.
  34. Will Qiagen's Restructuring Address The Real Problems?

    November 30, 2011
    Will Qiagen's Restructuring Address The Real Problems?
  35. 5 Oversold Stocks To Watch

    October 19, 2011
    Let's take a look at a few stocks that have recently entered oversold territory because these could be candidates for a short-term ...
  36. Affymetrix's Downward Spiral Continues

    July 7, 2011
    Affymetrix continues to flounder with unexciting technology.
  37. Some Stocks Have Held Up Well

    June 22, 2011
    Surprisingly, many stocks have held up recently and could be offering an opportunity.
  38. Illumina Lights Up Again

    April 29, 2011
    Illumina is a torrid grower, and growth investors seem to be willing to pay any price.
  39. Thermo Fisher Pays A High Price For Quality

    December 15, 2010
    Thermo Fisher makes a very reasonable purchase but pays a price to do so.
  40. The Stock-Split Portfolio

    December 6, 2010
    Many investors debate the merits of a stock split, but the bottom line doesn't lie. Find out how companies who split their ...
  41. A Fistfull Of Life Sciences

    October 29, 2010
    The life sciences field is showing encouraging growth and mostly reasonable valuations.
  42. The Next-Gen Sequencing Pot Keeps Bubbling

    August 23, 2010
    Last week saw two major developments in one of the fastest-growing arenas of life science.
  43. Sequencing Wars - The Third Generation

    June 10, 2010
    Life sciences companies are gearing up for a battle that could decide hundreds of millions of dollars in revenue and the ...
  44. Small Med-Tech Names You Should Know

    April 15, 2010
    These three med-tech names aren't well-known by most investors, but they should be.
  45. Biotech Stocks Looking Strong

    March 9, 2010
    Biotech Stocks Looking Strong
  46. Stock Splits Worth A Look

    May 11, 2009
    What does the decline in stock splits mean for investors?
  47. Affymetrix Misses Revenue Again And Again

    October 16, 2008
    Affymetrix missed revenue for the third consecutive quarter and blamed weak sales on a weak market - something competitors ...
  48. Getting Technical With Biotech

    July 11, 2008
    Watch as a blend of technical and fundamental analysis reveals hidden gems in this unpredictable sector.
Trading Center